Drug intelligence / Profile preview

QL1706 + carboplatin + paclitaxel + pemetrexed

Development stage: Unknown
Lead developer: Qilu Pharmaceutical
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules
Administration: Intravenous

Overview

QL1706 + carboplatin + paclitaxel + pemetrexed is a combination therapy consisting of a novel bifunctional antibody (QL1706) with chemotherapy agents. QL1706 (also known as PSB205) is a bifunctional antibody that contains a mixture of anti-PD-1 IgG4 and anti-CTLA-4 IgG1 antibodies produced by a single cell line using MabPair technology. This combination targets both PD-1 and CTLA-4 immune checkpoints simultaneously, producing synergistic anti-tumor effects. The chemotherapy components (carboplatin, paclitaxel, and pemetrexed) are standard cytotoxic agents used in cancer treatment. This combination is being investigated for the treatment of advanced non-small cell lung cancer (NSCLC).

Other names: iparomlimab and tuvonralimab + carboplatin + paclitaxel + pemetrexed

Targets

CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)PDCD1 (Programmed cell death protein 1 receptor)

Beyond the preview

Go deeper on QL1706 + carboplatin + paclitaxel + pemetrexed.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on QL1706 + carboplatin + paclitaxel + pemetrexed.

Explore the full profile